About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Effects of DPP4 Inhibition on COVID-19 | Clinical Trials | Clareo Health

Back to clinical trial search

WITHDRAWNPhase 4NCT04341935

Effects of DPP4 Inhibition on COVID-19

The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-...

Lead sponsor: University of Miami•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Miami

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines
•Age ≥ 18
•Confirmed COVID-19
•Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore throat, myalgia, nasal congestion, diarrhea
•Moderate COVID-19 is defined as \> 2 of the following in non-intubated patients: any symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with bilateral ground glass opacities or bilateral consolidations, SpO2 \<90% up to 5L Nasal Cannula (NC)
•No additional signs or symptoms of severe COVID-19.

Exclusion Criteria

•Type 1 Diabetes Mellitus (T1DM) diabetes, as per ADA guidelines
•History of Diabetic Ketoacidosis (DKA)
•History of acute pancreatitis
•Chronic or Acute Renal Failure with Estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1.73 m2
•T1DM diabetes, as per ADA guidelines, History of DKA, History of acute pancreatitis; Chronic or Acute Renal Failure with eGFR \< 30 ml/min/1.73 m2

Related studies

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

NCT07187830 · Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight

RECRUITINGPhase 4

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

NCT06613854 · Type 2 Diabetes Mellitus (T2DM)

RECRUITINGPhase 3

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287 · Long COVID, Sars-CoV-2 Infection, and more

Using Virtual Reality to Improve Medical Training

NCT07542834 · Type 2 Diabetes (T2DM), Geriatric Syndromes, and more

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

NCT07272837 · Type 2 Diabetes, Obesity, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 10, 2021Terms

Trial snapshot

StatusWITHDRAWN

PhasePHASE4

Enrollment—

Start dateJun 2021

Last updatedJun 10, 2021

Condition

Coronavirus Infection Type 2 Diabetes

Locations shown

University of Miami

Miami, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 10, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions